80%Confidence
0Views
FDASource
2026-04-14Date
Summary
Macleods Pharma USA's Class II recall for subpotent Levothyroxine Sodium Tablets suggests manufacturing quality issues, which could affect market share and trust in its thyroid medication. This may lead to increased regulatory oversight and potential competitive inroads by rivals.
Actionable: Assess competitive thyroid drug manufacturers for potential market share gains.
AI Confidence: 80%
Data Points
firmMACLEODS PHARMA USA, INC
classificationClass II
statusOngoing
distributionNationwide
productLevothyroxine Sodium Tablets USP 150 mcg, 1000 Tablets bottle, Rx Only, Manufactured for: Macleods Pharma USA, Inc., Princeton, NJ, Manufactured by: M
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now